2020
Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
Gale M, Li Y, Cao J, Liu ZZ, Holmbeck MA, Zhang M, Lang SM, Wu L, Do Carmo M, Gupta S, Aoshima K, DiGiovanna MP, Stern DF, Rimm DL, Shadel GS, Chen X, Yan Q. Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition. Cancer Research 2020, 80: 524-535. PMID: 31690671, PMCID: PMC7002225, DOI: 10.1158/0008-5472.can-18-3985.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBreast NeoplasmsCell ProliferationDrug Resistance, NeoplasmEnzyme InhibitorsFemaleHumansMiceMice, Inbred NODMice, SCIDMitochondrial Proton-Translocating ATPasesOligomycinsReceptor, ErbB-2TrastuzumabTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsResistant cellsHER2-Targeted TherapyTrastuzumab-resistant tumorsNew therapeutic strategiesNovel potential targetDrug-free mediumAntibody therapySynthase inhibitionLow doseTherapeutic strategiesTrastuzumabBreast tumorsHER2TherapyAcquired ResistanceTumorsPotential targetMitochondrial respirationCellsSelective dependencyInhibitionMinimal changesNovel vulnerabilitiesATP synthase inhibitionOligomycin A
1996
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.
Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. American Journal Of Pathology 1996, 148: 549-58. PMID: 8579117, PMCID: PMC1861670.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsErbB ReceptorsFemaleFrozen SectionsGenes, erbB-2HumansImmunohistochemistryPhosphorylationPhosphotyrosinePrognosisProto-Oncogene MasReceptor Protein-Tyrosine KinasesReceptor, ErbB-2Receptor, ErbB-4Receptors, EstrogenReceptors, ProgesteroneReceptors, SteroidRetrospective StudiesConceptsMammary carcinomaReceptor tyrosine kinasesType 1 receptor tyrosine kinasesMammary carcinoma patientsType 1 receptorExpression of neuAnti-neu antibodyEpidermal growth factor receptorGrowth factor receptorTyrosine kinaseCarcinoma patientsPrognostic factorsPoor prognosisClinical evaluationTherapeutic strategiesCarcinomaHER-4Frozen sectionsSteroid receptorsNeu/ErbBNeuFactor receptorReceptorsDifferent biological activitiesTyrosine phosphorylation